186 related articles for article (PubMed ID: 23894404)
1. Tumor site- and stage-specific associations between allelic variants of glutathione S-transferase and DNA-repair genes and overall survival in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
Lai CY; Hsieh LL; Sung FC; Tang R; Bai CH; Wu FY; Chiou HY; Yeh CC
PLoS One; 2013; 8(7):e69039. PubMed ID: 23894404
[TBL] [Abstract][Full Text] [Related]
2. Association between polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln genes and prognosis of colorectal cancer in a Chinese population.
Gan Y; Li XR; Chen DJ; Wu JH
Asian Pac J Cancer Prev; 2012; 13(11):5721-4. PubMed ID: 23317245
[TBL] [Abstract][Full Text] [Related]
3. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer.
Lamas MJ; Duran G; Balboa E; Bernardez B; Touris M; Vidal Y; Gallardo E; Lopez R; Carracedo A; Barros F
Pharmacogenomics; 2011 Mar; 12(3):433-42. PubMed ID: 21449681
[TBL] [Abstract][Full Text] [Related]
4. Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India.
Sreeja L; Syamala VS; Syamala V; Hariharan S; Raveendran PB; Vijayalekshmi RV; Madhavan J; Ankathil R
J Cancer Res Clin Oncol; 2008 Jun; 134(6):645-52. PubMed ID: 17952468
[TBL] [Abstract][Full Text] [Related]
5. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
Stoehlmacher J; Park DJ; Zhang W; Yang D; Groshen S; Zahedy S; Lenz HJ
Br J Cancer; 2004 Jul; 91(2):344-54. PubMed ID: 15213713
[TBL] [Abstract][Full Text] [Related]
6. Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy.
Lai CY; Sung FC; Hsieh LL; Tang R; Chiou HY; Wu FY; Yeh CC
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S599-606. PubMed ID: 23800895
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy.
Funke S; Timofeeva M; Risch A; Hoffmeister M; Stegmaier C; Seiler CM; Brenner H; Chang-Claude J
Pharmacogenomics; 2010 Jan; 11(1):33-41. PubMed ID: 20017670
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy.
Yeh CC; Lai CY; Chang SN; Hsieh LL; Tang R; Sung FC; Lin YK
Int J Clin Oncol; 2017 Jun; 22(3):484-493. PubMed ID: 28044213
[TBL] [Abstract][Full Text] [Related]
9. Impact of XRCC1, GSTP1, and GSTM1 Polymorphisms on the Survival of Ovarian Carcinoma Patients Treated with Chemotherapy.
Zhai XH; Huang J; Wu FX; Zhu DY; Wang AC
Oncol Res Treat; 2016; 39(7-8):440-6. PubMed ID: 27487108
[TBL] [Abstract][Full Text] [Related]
10.
Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
[TBL] [Abstract][Full Text] [Related]
11. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
[TBL] [Abstract][Full Text] [Related]
12. Association between genetic polymorphisms in the XRCC1, XRCC3, XPD, GSTM1, GSTT1, MSH2, MLH1, MSH3, and MGMT genes and radiosensitivity in breast cancer patients.
Mangoni M; Bisanzi S; Carozzi F; Sani C; Biti G; Livi L; Barletta E; Costantini AS; Gorini G
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):52-8. PubMed ID: 20708344
[TBL] [Abstract][Full Text] [Related]
13. Genetic variants in the glutathione S-transferase genes and survival in colorectal cancer patients after chemotherapy and differences according to treatment with oxaliplatin.
Kap EJ; Richter S; Rudolph A; Jansen L; Ulrich A; Hoffmeister M; Ulrich CM; Brenner H; Chang-Claude J
Pharmacogenet Genomics; 2014 Jul; 24(7):340-7. PubMed ID: 24842074
[TBL] [Abstract][Full Text] [Related]
14. DNA repair XRCC1 Arg399Gln polymorphism is associated with the risk of development of end-stage renal disease.
Trabulus S; Guven GS; Altiparmak MR; Batar B; Tun O; Yalin AS; Tunckale A; Guven M
Mol Biol Rep; 2012 Jun; 39(6):6995-7001. PubMed ID: 22302399
[TBL] [Abstract][Full Text] [Related]
15. DNA repair genes polymorphism and lung cancer risk with the emphasis to sex differences.
Letkova L; Matakova T; Musak L; Sarlinova M; Krutakova M; Slovakova P; Kavcova E; Jakusova V; Janickova M; Drgova A; Berzinec P; Halasova E
Mol Biol Rep; 2013 Sep; 40(9):5261-73. PubMed ID: 23673479
[TBL] [Abstract][Full Text] [Related]
16. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.
Etienne-Grimaldi MC; Milano G; Maindrault-Goebel F; Chibaudel B; Formento JL; Francoual M; Lledo G; André T; Mabro M; Mineur L; Flesch M; Carola E; de Gramont A
Br J Clin Pharmacol; 2010 Jan; 69(1):58-66. PubMed ID: 20078613
[TBL] [Abstract][Full Text] [Related]
17. XRCC1, XRCC3, and XPD polymorphisms as modifiers of the effect of smoking and alcohol on colorectal adenoma risk.
Stern MC; Siegmund KD; Conti DV; Corral R; Haile RW
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2384-90. PubMed ID: 17164360
[TBL] [Abstract][Full Text] [Related]
18. DNA repair genes XPD and XRCC1 polymorphisms and risk of end-stage renal disease in Egyptian population.
Radwan WM; Elbarbary HS; Alsheikh NM
Ren Fail; 2015 Feb; 37(1):122-8. PubMed ID: 25310768
[TBL] [Abstract][Full Text] [Related]
19. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer.
Stoehlmacher J; Park DJ; Zhang W; Groshen S; Tsao-Wei DD; Yu MC; Lenz HJ
J Natl Cancer Inst; 2002 Jun; 94(12):936-42. PubMed ID: 12072547
[TBL] [Abstract][Full Text] [Related]
20. The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.
Artac M; Bozcuk H; Pehlivan S; Akcan S; Pehlivan M; Sever T; Ozdogan M; Savas B
J Cancer Res Clin Oncol; 2010 Jun; 136(6):803-9. PubMed ID: 19908066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
